Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic Modelling

NCT06298123 · clinicaltrials.gov ↗

COMPLETED

Status

304

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma
Adjuvant Immunotherapy
Checkpoint Inhibitor

Interventions

DRUG: Anti-PD-1 monoclonal antibody

Sponsor

Chen Xiaoping